Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Audio By Carbonatix

BOSTON--(BUSINESS WIRE)--Apr 7, 2025--

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 164,500 shares of its common stock to fourteen new employees and the grant of 83,333 restricted stock units to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price equal to $5.82 per share, the closing price of Verastem Oncology’s common stock as reported by Nasdaq on April 1, 2025. The stock options to purchase 164,500 shares of common stock granted to fourteen new employees and 50,000 restricted stock units granted to one new employee will vest at a rate of twenty-five percent (25%) on the one-year anniversary of the employee’s date of hire, with the remaining shares vesting quarterly over the next three (3) years in equal quarterly amounts, provided the employee continues to serve as an employee of or other service provider to Verastem Oncology on each such vesting date. 33,333 restricted stock units granted to one new employee will vest upon the achievement of certain sales milestones, provided that the employee continues to serve as an employee of or other service provider to Verastem Oncology on each such vesting date.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250407925188/en/

CONTACT: For Investor and Media Inquiries:

Julissa Viana

Vice President, Corporate Communications

Investor Relations and Patient Advocacy

[email protected]

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY

SOURCE: Verastem Oncology

Copyright Business Wire 2025.

PUB: 04/07/2025 07:30 AM/DISC: 04/07/2025 07:31 AM

http://www.businesswire.com/news/home/20250407925188/en